People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase 3 trial to test its highly-anticipated weight loss therapy, CagriSema, after a December readout failed to meet investors ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...